VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+8.21%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$214M
AUM Growth
+$9.71M
(+4.8%)
Cap. Flow
+$1.5M
Cap. Flow
% of AUM
0.7%
Top 10 Holdings %
Top 10 Hldgs %
6.68%
Holding
490
New
42
Increased
186
Reduced
165
Closed
36
Top Buys
| 1 |
OCCI
OFS Credit Co
OCCI
|
$2.06M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
$1.96M |
| 3 |
Applovin
APP
|
$1.49M |
| 4 |
Constellation Energy
CEG
|
$1.32M |
| 5 |
ECC
Eagle Point Credit Co
ECC
|
$1.26M |
Top Sells
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
$1.49M |
| 2 |
Gen Digital
GEN
|
$1.01M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$1M |
| 4 |
Adobe
ADBE
|
$989K |
| 5 |
Steris
STE
|
$907K |
Sector Composition
| 1 | Financials | 28.16% |
| 2 | Healthcare | 18.37% |
| 3 | Technology | 14.33% |
| 4 | Industrials | 8.16% |
| 5 | Consumer Discretionary | 6.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Protagonist Therapeutics
PTGX
$3.77B
| $121K | 0.06% |
2,680
+45
| +2% | +$2.03K |
|
352
Ecopetrol
EC
$18.7B
| $120K | 0.06% |
13,484
-2,962
| -18% | -$26.5K |
|
353
GeoPark
GPRK
$326M
| $120K | 0.06% |
15,205
-3,874
| -20% | -$30.5K |
|
354
Nuvalent
NUVL
$5.83B
| $119K | 0.06% |
1,165
+19
| +2% | +$1.94K |
|
355
Wave Life Sciences
WVE
$1.32B
| $117K | 0.05% |
14,222
+252
| +2% | +$2.07K |
|
356
Disc Medicine
IRON
$2.11B
| $116K | 0.05% |
2,353
+41
| +2% | +$2.02K |
|
357
Erasca
ERAS
$457M
| $115K | 0.05% |
42,275
+749
| +2% | +$2.05K |
|
358
Arbutus Biopharma
ABUS
$805M
| $112K | 0.05% |
29,162
+515
| +2% | +$1.98K |
|
359
Viking Therapeutics
VKTX
$3.03B
| $112K | 0.05% |
1,771
+33
| +2% | +$2.09K |
|
360
Cogent Biosciences
COGT
$1.82B
| $111K | 0.05% |
10,266
+185
| +2% | +$2K |
|
361
Tyra Biosciences
TYRA
$674M
| $109K | 0.05% |
4,642
+82
| +2% | +$1.93K |
|
362
MoonLake Immunotherapeutics
MLTX
$3.77B
| $109K | 0.05% |
2,162
+42
| +2% | +$2.12K |
|
363
Vera Therapeutics
VERA
$1.54B
| $109K | 0.05% |
2,465
+45
| +2% | +$1.99K |
|
364
Keros Therapeutics
KROS
$633M
| $108K | 0.05% |
1,859
+30
| +2% | +$1.74K |
|
365
Akero Therapeutics
AKRO
$3.58B
| $107K | 0.05% |
3,741
+64
| +2% | +$1.84K |
|
366
Enliven Therapeutics
ELVN
$1.19B
| $107K | 0.05% |
4,188
+77
| +2% | +$1.97K |
|
367
Replimune Group
REPL
$494M
| $107K | 0.05% |
9,739
+170
| +2% | +$1.86K |
|
368
Perspective Therapeutics
CATX
$257M
| $106K | 0.05% |
7,945
+142
| +2% | +$1.9K |
|
369
Avidity Biosciences
RNA
$6.48B
| $106K | 0.05% |
2,305
+40
| +2% | +$1.84K |
|
370
Revolution Medicines
RVMD
$7.57B
| $105K | 0.05% |
2,321
+43
| +2% | +$1.95K |
|
|
SLRN
371
DELISTED
ACELYRIN
SLRN
| $104K | 0.05% |
21,138
+375
| +2% | +$1.85K |
|
372
Soleno Therapeutics
SLNO
$3.71B
| $104K | 0.05% |
2,050
+39
| +2% | +$1.97K |
|
373
Allogene Therapeutics
ALLO
$246M
| $102K | 0.05% |
36,285
+645
| +2% | +$1.81K |
|
374
Crinetics Pharmaceuticals
CRNX
$3.35B
| $100K | 0.05% |
1,962
+31
| +2% | +$1.58K |
|
375
CG Oncology
CGON
$2.52B
| $99.9K | 0.05% |
2,648
+47
| +2% | +$1.77K |
|